1.91
-0.03 (-1.55%)
| Previous Close | 1.94 |
| Open | 1.95 |
| Volume | 15,497 |
| Avg. Volume (3M) | 47,365 |
| Market Cap | 89,979,336 |
| Price / Sales | 846.47 |
| Price / Book | 1.81 |
| 52 Weeks Range | |
| Earnings Date | 23 Jul 2025 - 28 Jul 2025 |
| Operating Margin (TTM) | -17,082.39% |
| Diluted EPS (TTM) | -0.740 |
| Quarterly Revenue Growth (YOY) | -87.30% |
| Total Debt/Equity (MRQ) | 36.60% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | -29.70 M |
| Levered Free Cash Flow (TTM) | -18.87 M |
| Return on Assets (TTM) | -21.92% |
| Return on Equity (TTM) | -55.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Adagene Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | -1.17 |
|
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.70% |
| % Held by Institutions | 34.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wuxi Apptec Co., Ltd. | 30 Sep 2024 | 3,982,902 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2025 | 199,610 |
| Fifth Lane Capital, Lp | 31 Mar 2025 | 27,500 |
| Gordian Capital Singapore Pte Ltd | 31 Mar 2025 | 18,900 |
| Catalina Capital Group, Llc | 31 Mar 2025 | 0 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |